Infinity/ Bristol-Myers Adds TNBC Patients To Clinical Deal
Zacks Investment Research | Sep 25, 2017 10:24PM ET
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) announced that it has expanded its existing clinical collaboration with Bristol-Myers Squibb (NYSE:BMY) for evaluating IPI-549 in combination with latter’s checkpoint inhibitor Opdivo. The collaboration will include patients with triple negative breast cancer (TNBC), who have not been previously exposed to anti-PD-1 or anti-PD-L1 therapy.
Very few patients with triple negative breast cancer respond to checkpoint inhibitors alone and so they are left with very limited therapeutic options. Thus expanding the collaboration to include patients with triple negative breast cancer (TNBC), who have not been previously exposed to anti-PD-1 or anti-PD-L1 therapy. This, in turn, will enable Infinity to test whether IPI-549 in combination with Opdivo can increase the number of patients who respond to checkpoint inhibition.
Markedly, IPI-549 is the lead pipeline candidate of Infinity Pharmaceuticals and is being evaluated in a phase I/Ib study for the treatment of patients with solid tumors. It is an orally administered treatment that selectively inhibits phosphoinositide-3 kinase (PI3K)-gamma.
In November 2016, Infinity entered into a clinical trial collaboration with Bristol-Myers to evaluate IPI-549 in combination with Opdivo in patients with advanced solid tumors.
Meanwhile, Opdivo is approved for varied indications in the EU and the United States. Also, it has received approvals for several indications including melanoma, head and neck, lung, kidney and blood cancer.
However, Infinity’s shares have underperformed the industry year to date. The stock has been down 10.4%, as against the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.